EP2061493A4 - Compositions pour réduire ou prévenir le cancer de la peau - Google Patents

Compositions pour réduire ou prévenir le cancer de la peau

Info

Publication number
EP2061493A4
EP2061493A4 EP06789889A EP06789889A EP2061493A4 EP 2061493 A4 EP2061493 A4 EP 2061493A4 EP 06789889 A EP06789889 A EP 06789889A EP 06789889 A EP06789889 A EP 06789889A EP 2061493 A4 EP2061493 A4 EP 2061493A4
Authority
EP
European Patent Office
Prior art keywords
compositions
reduce
skin cancer
prevent skin
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06789889A
Other languages
German (de)
English (en)
Other versions
EP2061493A1 (fr
Inventor
Zoltan Kiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Essential SkinCare LLC
Original Assignee
Essential SkinCare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Essential SkinCare LLC filed Critical Essential SkinCare LLC
Publication of EP2061493A1 publication Critical patent/EP2061493A1/fr
Publication of EP2061493A4 publication Critical patent/EP2061493A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP06789889A 2006-08-21 2006-08-21 Compositions pour réduire ou prévenir le cancer de la peau Withdrawn EP2061493A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/032549 WO2008024103A1 (fr) 2006-08-21 2006-08-21 Compositions pour réduire ou prévenir le cancer de la peau

Publications (2)

Publication Number Publication Date
EP2061493A1 EP2061493A1 (fr) 2009-05-27
EP2061493A4 true EP2061493A4 (fr) 2011-01-12

Family

ID=39107080

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06789889A Withdrawn EP2061493A4 (fr) 2006-08-21 2006-08-21 Compositions pour réduire ou prévenir le cancer de la peau

Country Status (2)

Country Link
EP (1) EP2061493A4 (fr)
WO (1) WO2008024103A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3345614A1 (fr) * 2017-01-05 2018-07-11 Amrif B.V. Composition comprenant de la phosphatase alcaline destinée à être utilisée dans le traitement des arthrites
WO2018175413A1 (fr) 2017-03-21 2018-09-27 Synthetic Biologics, Inc. Formulations de phosphatase alcaline
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
ES3032290T3 (en) 2018-03-20 2025-07-16 Theriva Biologics Inc Intestinal alkaline phosphatase formulations
US11654184B2 (en) 2018-03-20 2023-05-23 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
JP7660523B2 (ja) 2019-05-06 2025-04-11 セリバ・バイオロジクス・インコーポレイテッド アルカリリン酸塩に基づいた癌治療

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302473A2 (fr) * 1987-08-04 1989-02-08 Bristol-Myers Squibb Company Conjugues anticorps-enzyme associés à des prodrogues pour la libération d'agents cytotoxyques dans les cellules tumorales
US20020177583A1 (en) * 2001-03-29 2002-11-28 Zoltan Kiss Methods and compositions for the treatment of human and animal cancers
WO2007075199A1 (fr) * 2005-12-28 2007-07-05 Zoltan Laboratories Llc Utilisation de phosphatase alcaline pour le maintien de la masse de tissus sains chez des mammiferes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374754B2 (en) * 2003-09-02 2008-05-20 Essential Skincare, Llc Use of placental alkaline phosphatase to promote skin cell proliferation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302473A2 (fr) * 1987-08-04 1989-02-08 Bristol-Myers Squibb Company Conjugues anticorps-enzyme associés à des prodrogues pour la libération d'agents cytotoxyques dans les cellules tumorales
US20020177583A1 (en) * 2001-03-29 2002-11-28 Zoltan Kiss Methods and compositions for the treatment of human and animal cancers
WO2007075199A1 (fr) * 2005-12-28 2007-07-05 Zoltan Laboratories Llc Utilisation de phosphatase alcaline pour le maintien de la masse de tissus sains chez des mammiferes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2008024103A1 *

Also Published As

Publication number Publication date
EP2061493A1 (fr) 2009-05-27
WO2008024103A1 (fr) 2008-02-28

Similar Documents

Publication Publication Date Title
GB0719161D0 (en) Improvements relating to fabrick treatment compositions
EP2365815A4 (fr) Compositions de matrice extracellulaire pour le traitement du cancer
AP2008004713A0 (en) Improvements relating to anti-parasetic compositions
EP2116224A4 (fr) Composition cosmétique
PL3067054T3 (pl) Nowe kompozycje i sposoby leczenia nowotworów
PL2059223T3 (pl) Kompozycja do pielęgnacji skóry
GB0712991D0 (en) Improvement in or relating to compositions
PL2061561T3 (pl) Kompozycje do leczenia raka
ZA200905508B (en) Compositions and methods to prevent cancer with cupredoxins
GB2458228B (en) External preparation for skin
IL197602A0 (en) Compositions and methods to prevent cancer with cupredoxins
PL2209458T3 (pl) Kompozycje do traktowania skóry
IL197235A0 (en) Therapeutic compositions
IL238394B (en) Preparations containing a combination of factors for the treatment of cancer
PL1863899T3 (pl) Kompozycje do leczenia skóry
GB0702931D0 (en) Skin application
GB0611743D0 (en) Skincare composition
EP2039340A4 (fr) Composition de nettoyage de la peau
ZA200806185B (en) Antiperspirant compositions
EP1979487A4 (fr) Compositions de cobalamine pour le traitement du cancer
GB0908728D0 (en) Skin cleansing compositions
GB2456476A8 (en) Composition for skin or mucosal application
EP2061493A4 (fr) Compositions pour réduire ou prévenir le cancer de la peau
GB0622847D0 (en) Cosmetic composition
EP2056839A4 (fr) Approches combinées pour le traitement du cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090320

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20101213

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20101207BHEP

Ipc: A61K 38/57 20060101ALI20101207BHEP

Ipc: A61K 38/46 20060101ALI20101207BHEP

Ipc: A61K 38/16 20060101AFI20080403BHEP

17Q First examination report despatched

Effective date: 20110830

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20130603